/ Published in 2025, Publication

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.
Watson-Jones D, Changalucha J, Maxwell C, Whitworth H, Mutani P, Kemp TJ, Kamala B, Indangasi J, Constantine G, Hashim R, Mwanzalima D, Wiggins R, Mmbando D, Connor N, Pavon MA, Lowe B, Kapiga S, Mayaud P, de Sanjosé S, Dillner J, Hayes RJ, Lacey CJ, Pinto L, Baisley K.
Lancet Glob Health. 2025 Feb;13(2):e319-e328.
DOI: 10.1016/S2214-109X(24)00477-7.
PMID: 39890232;
PMCID: PMC11783036.

What you can read next

EMPOWER study team. Exploring the feasibility and acceptability of integrating screening for gender- based violence into HIV counselling and testing for adolescent girls and young women in Tanzania and South Africa.
Does a school-based intervention to engage parents change opportunity for handwashing with soap at home? Practical experience from the Mikono Safi trial in Northwestern Tanzania.
Risk factors for Herpes simplex virus type 2 and HIV among women at high risk in north-western Tanzania: preparing for an HSV-2 intervention trial. Journal of Acquired Immune Deficiency Syndromes 2007; 46: 631-642.